Home  »  Business   »  Atossa Therapeutics Inc. (NASDAQ: ATOS) Is Down -3...

Atossa Therapeutics Inc. (NASDAQ: ATOS) Is Down -36.88% So Far This Year. Analysts Expect A Significant Price Rally

Atossa Therapeutics Inc. (NASDAQ:ATOS) price closed lower on Friday, July 01, dropping -7.34% below its previous close.

A look at the daily price movement shows that the last close reads $1.09, with intraday deals fluctuated between $0.98 and $1.1006. The company’s 5Y monthly beta was ticking 1.96. Taking into account the 52-week price action we note that the stock hit a 52-week high of $7.15 and 52-week low of $0.84. The stock added 9.12% on its value in the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Atossa Therapeutics Inc., which has a market valuation of $127.89 million, is expected to release its quarterly earnings report Mar 29, 2022 – Apr 04, 2022. Analysts tracking ATOS have forecast the quarterly EPS to shrink by -0.05 per share this quarter, while the same analysts predict the annual EPS to hit -$0.2 for the year 2022 and up to -$0.19 for 2023. In this case, analysts estimate an annual EPS growth of -11.10% for the year and 5.00% for the next year.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ATOS a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned ATOS a recommendation rating as follows: 0 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Atossa Therapeutics Inc. (ATOS) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that ATOS’s price is at present -7.57% off the SMA20 and -1.47% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 45.05, with weekly volatility standing at 7.98%. The indicator jumps to 8.80% when calculated based on the past 30 days. Atossa Therapeutics Inc. (NASDAQ:ATOS)’s beta value is holding at 1.82, while the average true range (ATR) indicator is currently reading 0.09. Considering analysts have assigned the stock a price target range of $7.50-$7.50 as the low and high respectively, we find the trailing 12-month average consensus price target to be $7.50. Based on this estimate, we see that current price is roughly -642.57% off the estimated low and -642.57% off the forecast high. Investors will no doubt be excited to see the share price fall to $7.50, which is the median consensus price, and at that level ATOS would be -642.57% from current price.

An analysis of the Atossa Therapeutics Inc. (NASDAQ:ATOS) stock in terms of its daily trading volume indicates that the 3-month average is 1.82 million.

Current records show that the company has 126.62M in outstanding shares. The insiders’ percentage holdings are 0.04% of outstanding shares while the percentage share held by institutions stands at 35.00%. But the -36.88% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]